Term
| WHO criteria for metabolic syndrome - 5 |
|
Definition
BP >140/90 or on anti-HTN
TG >150 or HDL <39
BMI 30+ or W:H >0.85
insulin resistance or DM2
microalbuminia 20+ mcg/m or A:Cr 30+
need insulin resistance and 2 criteria OR
no resistance and 3 criteria |
|
|
Term
| combined metabolic syndrome criteria - 9 |
|
Definition
BP >130-140/85-90 or on anit-HTN
waist >/= 35in
W:H >0.85
BMI 30+
BG >/= 110 or insulin resistance
TG >150
HDL <45-50
microalbumin >20
A:Cr >30 |
|
|
Term
| management metabolic syndrome - 4 |
|
Definition
| diet, exercise, weight loss, metformin |
|
|
Term
| non-pregnant DM screening ACOG |
|
Definition
| FHX, hx GDM, obesity -> fasting BG q3-5y |
|
|
Term
| non-pregnancy DM screening ADA |
|
Definition
| >45yo and obese OR BMI 25+ with risk factor do fasting or A1C |
|
|
Term
|
Definition
|
|
Term
| lipid risk factors for DM2 |
|
Definition
|
|
Term
|
Definition
polyuria, polydypsia, weight loss + random glucose 200+
OR
2 of these - Fasting 126+, 2h 200+, A1C 6.5+ |
|
|
Term
| diagnosis of pre-diabetes |
|
Definition
fasting 100-125
2h 140-199
A1c 5.7-6.4 |
|
|
Term
| yearly prevention for DM - 7 |
|
Definition
| optho, nutrition, foot exam, lipids, microalbumin (5y after onset DM1), EKG, flu |
|
|
Term
| weight loss goal diabetes |
|
Definition
|
|
Term
| when to start and add meds in DM2 |
|
Definition
3mo A1C 7+ start med
6mo still 7+ add another |
|
|
Term
| A1C goal in DM, how often to monitor |
|
Definition
|
|
Term
| MOA metformin / glucophage |
|
Definition
| decreased hepatic glucose production, increased intestinal absorption, increased insulin action |
|
|
Term
| glucophage - effect on weight gain, hypoglycemia, and CV events/mortality |
|
Definition
no weight changes or hypoglycemia
decreased CV |
|
|
Term
| thiazolidinediones - effect on weight gain, hypoglycemia, and CV events/mortality |
|
Definition
weight gain possible, no hypoglycemia
increases HDL and decreased TG, can cause CHF |
|
|
Term
| GLPL1 receptor agonist - effect on weight gain, hypoglycemia, and CV events/mortality |
|
Definition
| weight loss, ?glycemia, no comment on cardio |
|
|
Term
| DPP4 inhibitors - - effect on weight gain, hypoglycemia, and CV events/mortality |
|
Definition
no hypoglycemia, weight neutral
no comment on cardio |
|
|
Term
|
Definition
| tolbutamine, chlorpropramide, glyburide, glipizide, glimiperide |
|
|
Term
|
Definition
|
|
Term
| GlP1 receptor agonists - 2 |
|
Definition
| exenatide/buderon, liraglutide/victoza |
|
|
Term
|
Definition
| stigliptin, vildagliptin, saxagliptin, linagliptin |
|
|
Term
|
Definition
| invokana/canagglifolzin, faxiga/dapagliflozin, jardance/empagliflozin |
|
|
Term
|
Definition
| increases insulin secretion |
|
|
Term
|
Definition
| increased peripherial insulin sensitivity |
|
|
Term
| GLP1 receptor agonists MOA |
|
Definition
| glucagon like peptide 1, insulin secretion increased, glucagon secretion decreased, slows gastric emptying |
|
|
Term
|
Definition
| inncreases incretin in gut, increases on demand insulin, decreases glucagon |
|
|
Term
|
Definition
|
|
Term
|
Definition
| diarrhea, lactic acidosis, B12 deficiency |
|
|
Term
| contraindications metformin - 1 |
|
Definition
|
|
Term
|
Definition
| hypoglycemia, weight gain |
|
|
Term
| thiazolidinediones SE - 4 |
|
Definition
| weight gain, edema, CHF, bone fractures |
|
|
Term
| GLP1 receptor agonist SE - 3 |
|
Definition
| weight loss, GI sx, acute pancreatitis, medullary thyroid tumors |
|
|
Term
|
Definition
| uticaria, angioedema, pancreatitis |
|
|
Term
|
Definition
| yeast infection, fornuiers gangrene |
|
|
Term
| how to divvy up insulin in a new DM2 needing meds |
|
Definition
| 0.6 U/kg/d, 1/2 at bedtime, 1/2 at meals |
|
|
Term
| when to increase insulin in DM2 |
|
Definition
| increase 2-4U if fasting >130 |
|
|
Term
|
Definition
aspart/novorapid
glylizine/apidra
lispro/humalog |
|
|
Term
| short acting insulin types - 3 |
|
Definition
| regular = humilinR, novilinR, grTronto |
|
|
Term
| intermdiate insulin types - 2 |
|
Definition
| NPH - humulinN, novolin NPH |
|
|
Term
| long acting insulin types - 2 |
|
Definition
detemir/levemir
glargine/lantus |
|
|
Term
| rapid insulin - onset, peak, duration |
|
Definition
|
|
Term
| short insulin - onset, peak, duration |
|
Definition
|
|
Term
| intermediate insulin - - onset, peak, duration |
|
Definition
|
|
Term
| long acting insulin - onset, peak, duration |
|
Definition
|
|
Term
| what complications of DM might a type 2 be unable to control just with glucose control |
|
Definition
|
|
Term
| most common complication of pregnancy |
|
Definition
|
|
Term
|
Definition
| HPL and insulinase both made by placenta |
|
|
Term
| criteria for early GDM screening |
|
Definition
BMI 25+ with one (FHX DM, inactivity, AA, latino, native A, asian , PI, prior >4000g, prior GDM, HTN, HDL <35, TG >250, PCOS, acanthosis, CVD)
BMI >40
A1C >5.7 |
|
|
Term
| 1h GTT is at how many weeks and how much glucose |
|
Definition
|
|
Term
|
Definition
| increases diagnosis to 18% from 7% without improvement in outcomes and increased cost |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| pre-eclampsia/HTN, operative delivery, DM2, weight gain >40 lbs |
|
|
Term
|
Definition
| 1/3 remain DM postpartum, 50% lifetime risk |
|
|
Term
| #1 and 2 most common fetal risks of GDM and % |
|
Definition
hypoglycemia 50%
macrosomia 30-40% |
|
|
Term
| congenital anomalies associated with GDM and % - 4 |
|
Definition
cardiac 2-5x
ONTD 2-5x
femoral hypoplasia unusual facies (20% of the syndrome patients were DM babies)
caudal regression |
|
|
Term
| fetal organ and metabolic changes associated with GDM - 7 |
|
Definition
| polyhydraminos, HSM, cardiomeagly, RDS, hyperbilirubinemia, hypocalcemia, stillbirth |
|
|
Term
| what increases the already increased risk of stillbirth in GDM - 2 |
|
Definition
| poor glucose control, A1C >7 |
|
|
Term
| fetal risk specific to maternal ketosis |
|
Definition
|
|
Term
| incidence of polyhydraminos |
|
Definition
|
|
Term
| definition polyhydraminos |
|
Definition
| AFI >24, MVP >8, severe AFI 35+ |
|
|
Term
| causes of polyhydraminos - 2 categories and % |
|
Definition
| congenital 79%, idiopathic 50% |
|
|
Term
| causes of polyhydraminos - 13 |
|
Definition
| T18, GI abnormalities, chorioangina, CCAM, muscular dystrophy, ONTD, anancephaly, hydrancephaly, holoprosencephaly, DM, HTN, macrosomia, hydrops |
|
|
Term
| GI anomalies associated with polyhydraminos - 6 |
|
Definition
| esophageal atresia, TE fistula, SBO, hypoplastic jaw, swallowing disorders, abdominal wall defects |
|
|
Term
| # of CD needed to prevent 1 brachial plexus injury |
|
Definition
|
|
Term
| % of infants you thought were >4500g and really went |
|
Definition
|
|
Term
| when you can offer CD for macrosomia in GDM |
|
Definition
|
|
Term
| when to avoid operative delivery in macrosomia suspected patient |
|
Definition
| >4000g, prolonged second stage |
|
|
Term
| complications of fetal macrosomia - 3 |
|
Definition
| shoulder, clavicle fracture, brachial plexus injury |
|
|
Term
| causes of femoral hypoplasia unusual facies syndrome and % - 3 |
|
Definition
|
|
Term
| sings of femoral hypoplasia unusual facies syndrome - 19 |
|
Definition
upslanting eyes, short nose long tip, elongated pithilrym, thin upper lip,
macrognathia, clefts, low ears, hypoplastic femurs and UE, club foot, polydactyly, sindactyly, restricted elbow/shoulder ROM, inguinal hernias, pelvic/spinal abnormalities, PCKD/dysplasia, hypoplastic penis/labia, VSD, pulmonary stenosis, truncus arteriosis |
|
|
Term
| prognosis femoral hyopoplasia unusual facies syndrome |
|
Definition
|
|
Term
| caudal regression signs - 5 |
|
Definition
| sacral agenesis, sineromelia, renal agenesis, anal agensis, single umnbilical artery |
|
|
Term
| recommended kcal/d in GDM ideal, overweight morbid, underweight |
|
Definition
under - 40
ideal - 30
over - 25
morbid - 15 |
|
|
Term
| how meals are divided up in GDM |
|
Definition
10% breakfast
20% lunch
30% dinner
30% snacks |
|
|
Term
| how macros are broken down GDM |
|
Definition
40% carbs (complex high fiber)
20% protein
40% fats (<7% saturated) |
|
|
Term
| how many carbs per meal in GDM |
|
Definition
|
|
Term
| why do we use 1h PP in GDM - 4 |
|
Definition
| decreased A1c, better control, less macrosomia, lower CD |
|
|
Term
| goal fasting, 1h, 2h glucose GDM |
|
Definition
fast - 95
1h - 140
2h - 120 |
|
|
Term
| when to start or increase insulin GDM |
|
Definition
|
|
Term
| how much insulin to use per Kg in 1-3T |
|
Definition
1T 0.7
2T 0.8
3T 0.9
term 1.0
resistant... 1-2 |
|
|
Term
| how to break down insulin to start meds in GDM |
|
Definition
calculate daily - 2/3AM, 1/3PM
AM - 2/3 NPH, 1/3 rapid
PM- 1/2 NPH, 1/2 rapid |
|
|
Term
| how to use carb ratio instead of rapid insulin |
|
Definition
total units rapid needed a day / 500 = #
carb ration is 1:# |
|
|
Term
| why is metofmrin not first line |
|
Definition
| 26-46% will need insulin evuntally |
|
|
Term
|
Definition
2.5mg HS for elevated fasting
2.5mg breakfast for elevated PP
max 10mg/d |
|
|
Term
| why isnt glyburide used anymore - 6 |
|
Definition
| infant and maternal hypoglycemia and macrosomia, 4-16% will require insulin anyways, increased birth injury |
|
|
Term
| in GDM what does exercise help reduce |
|
Definition
|
|
Term
|
Definition
| check q2h, if >120 start drip at 1.25 U/h, stop if <70 and give 100-150 D5 |
|
|
Term
|
Definition
impaired: fasting 100-125, 2h 140-199
diabetes: fasting >126, 2h >200 |
|
|
Term
| how much glucose in 2h GTT |
|
Definition
|
|
Term
| when is a PP glucose test done |
|
Definition
|
|
Term
| if mom doesnt get PP diabetes, when is the next time she needs screenign |
|
Definition
|
|
Term
| 3 methods for diagnosis of HTN |
|
Definition
| 12-14 home values, continuous ambulatory values, 2 office values 2wk apart |
|
|
Term
| 4 requirements when taking a BP |
|
Definition
| seated for 5min, arm at level of heart, no caffeine or smoking within 30min |
|
|
Term
| values for each stage of HTN |
|
Definition
normal <120/80
elevated <130/80
stage 1 <140/90
stage 2 >140/90 |
|
|
Term
| when do you start meds for HTN |
|
Definition
| 130-140/90 if risk factors, >140/90 start meds |
|
|
Term
| when do you add a second HTN medication |
|
Definition
|
|
Term
| what are the target BP goals for HTN |
|
Definition
| <130/80 for most, <140/90 if labile BP, orthostatic hypotension, medication SE, >70yo, frail |
|
|
Term
| what is the follow up schedule for HTN medication starts |
|
Definition
| routine in 4-6wk, urgency q1wk |
|
|
Term
|
Definition
| EKG to rule out LVH, Cr to rule out renal, P:Cr if Cr is high, K+ to rule out aldosterone, renin:ald if K+ is high |
|
|
Term
| lifestyle modifications for HTH in order from most mmHg reduction to least - 5 |
|
Definition
| weight loss, diet change, exercise, Na reduction, smoking (no data on mmHg) |
|
|
Term
| how much does exercise decrease HTN |
|
Definition
|
|
Term
| how much does diet decrease HTN |
|
Definition
|
|
Term
| how much does weight loss decrease HTN |
|
Definition
|
|
Term
| how much does Na reduction decrease HTN |
|
Definition
|
|
Term
| 5 risk factors for essential HTN |
|
Definition
| Na, alcohol >2/d, obesity, AA, FHX |
|
|
Term
| causes of secondary HTN - 10 |
|
Definition
| renal, OSA, obesity, drugs, hyperthyroid, hyperparathyroid, aortic coarctation, cushings, pheochromocytoma, parimary hyper Ald / conns |
|
|
Term
| signs of renal disease causing HTN - 9 |
|
Definition
| bruit, hematuria, edema, severe HTN >55yo, increased Cr after ACEI, UL small or big/palpable kidney, increased Cr, proteinuria |
|
|
Term
| 3 drugs that can cause HTN |
|
Definition
|
|
Term
| signs of hyperparathyroidism - 8 |
|
Definition
| bone pain, kidney stones, psych disorders, polyuria, weight loss, weakness, apathy, Ca abnormalities |
|
|
Term
| signs of aortic coarctation - 10 |
|
Definition
| usually asymptomatic, HA, leg fatigue, epistaxis, pulse in neck, delayed peripherial pulses, bruit over back, BP different in each arm, CXR notching / 3 sign, abnormal ECHO |
|
|
Term
| signs of cushings disease - 9 |
|
Definition
| emotionally labile, muscle weakness, bruising, moon facies, central obesity, striae, osteoporosis, DM, hirsturism |
|
|
Term
| test for cushings disease |
|
Definition
|
|
Term
| signs of pheochromocytoma - 9 |
|
Definition
| palpitations, pallor, sweating, CP, HA, abd pain, tremor, weight loss, anxiety |
|
|
Term
| diagnosis of pehochromocytoma |
|
Definition
| urine and serum metanepherines |
|
|
Term
| lab changes in primary hypoaldosteronism - 2 |
|
Definition
|
|
Term
| 4 requirements if on OCPs with HTN |
|
Definition
| well controlled, non-smoker, no vascular disease, <35yo |
|
|
Term
|
Definition
| <180/120 without end organ damage |
|
|
Term
|
Definition
| medication non-compliance |
|
|
Term
| management of HTN urgency |
|
Definition
| goal <160/100 in hours to days, outpatient, q1wk check in |
|
|
Term
| define HTN emergency - 6 parts |
|
Definition
| >180/120 with end organ dysfunction - brain, visual changes, renal, cardiac, pulmonary, hemoglobin |
|
|
Term
| management of BP in HTN urgency |
|
Definition
| drop MAP by 10-20% in 1h then 5-15% in 23h, slowly reintroduce PO meds and wean off drip |
|
|
Term
| what does rapid HTN reversal cause |
|
Definition
|
|
Term
| meds used in drip for HTN emergency - 4 |
|
Definition
| nitroprusside (not ideal), nicardipine, labetalol, enlaprilat |
|
|
Term
| complications of nitroprusside drip |
|
Definition
| tachyphylaxis - diminishing response to successive doses of the drug |
|
|
Term
| what HTN meds are used in someone without comorbidities - 4 |
|
Definition
|
|
Term
| what HTN medications are used in CHF - 5 |
|
Definition
| ACEI, ARB, BB, HCTZ, aldosterone antagonists |
|
|
Term
| what medications are used in HTN with recent MI - 4 |
|
Definition
| ACEI, ARB, BB, aldosterone antagonist |
|
|
Term
| what medications are usedin HTN with CKD - 2 |
|
Definition
|
|
Term
| what HTN medications are used in CAD - 2 |
|
Definition
|
|
Term
| what HTN medications are used in AFib/flutter for rate control - 2 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| 500-3000mg/d in 2-3 doses |
|
|
Term
|
Definition
|
|
Term
| fetal SE of labetalol - 3 |
|
Definition
| IUGR, bradycardia, hypoglycemia |
|
|
Term
| maternal SE of labetalol - 8 |
|
Definition
| bronchospasm, increased uterine tone, CHF, headache, fatigue, elevated TG/VDRL, lowers HDL |
|
|
Term
| contraindications to labetalol - 3 |
|
Definition
| asthma, acute systolic CHF, conduction abnormalities |
|
|
Term
|
Definition
| vasodilation and decreased CO by inhibiting catecholamines at B adrenergic receptor |
|
|
Term
|
Definition
| vasodilation by blocking Ca uptake |
|
|
Term
|
Definition
| HA, tachycardia, orthostatic hypotension, edema, MI in CAD |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| sedation, elevated LFT / hepatitis, hemolysis, fever, depression |
|
|
Term
|
Definition
|
|
Term
|
Definition
| dizziness, headache, dry mouth |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| decrease plasma volume, venous return, CO, PVR by blocking Na reabsorption in distal convoluted tubule |
|
|
Term
|
Definition
|
|
Term
|
Definition
| volume depletion, electrolyte abnormalities, increased UA, low PLT, hypokalemia, arrhythmia |
|
|
Term
| what med should you be careful with on HCTZ and why |
|
Definition
| muscle relaxants, low K can potentiate their action |
|
|
Term
| monitoring required if on HCTZ |
|
Definition
| Cr and K 2wk post initiation |
|
|
Term
|
Definition
|
|
Term
|
Definition
| flushing, headache, SLE like reaction, tachycardia, hypotension |
|
|
Term
|
Definition
|
|
Term
| SE nitroprusside fetal - 1 |
|
Definition
|
|
Term
|
Definition
| cyanide toxicity, headache, nausea, vomiting |
|
|
Term
|
Definition
| HA, tachycardia, methemoglobinemia |
|
|
Term
| contraindication nitroglycerine - 1 |
|
Definition
|
|
Term
| why don't we use atenolol in pregnancy |
|
Definition
|
|
Term
|
Definition
| renal dysplasia, anuria/oligo, arterial hypotension, IUGR, RDS, pulmonary hypoplasia, limb defects, death |
|
|
Term
| why do you DC ACEI pre-op |
|
Definition
| prolonged hypotension during surgery |
|
|
Term
|
Definition
| cough 5-35% that improves in 1-4wk post DC, hyperkalemia, angioedema |
|
|
Term
| monitoring if on ACEI - 3 |
|
Definition
| Cr and K in 1-2wk after starting, if takes NSAIDS monitor Cr |
|
|
Term
|
Definition
| blocks angiotensin II Causing arterial and venous dilation and natiuresis |
|
|
Term
|
Definition
| blocks NE vasoconstriction in vascular smooth muscle |
|
|
Term
|
Definition
| syncope after 1st dose, stress incontinence, weakness, dizziness, decreased cholesterol and LDL, increased HDL |
|
|
Term
|
Definition
| direct relaxation of arterial wall smooth muscle |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| #1 cause of death in women |
|
Definition
| cardiovascular disease 44% |
|
|
Term
| risk reduction for cardiovascular disease - 8 |
|
Definition
| stop smoking, DASH, exercise, weight loss, control BP, control glucose, control lipids, ASA 81mg/d |
|
|
Term
| who gets ASA for cardiovascular disease prrevention |
|
Definition
|
|
Term
| describe cardiac chest pain - 8 |
|
Definition
| exertional, <20min, squeezing, heaviness, radiation, nausea, diaphoresis, agitation |
|
|
Term
| what are the 2 cardiac enzymes and their onset, peak, duration |
|
Definition
CPK - O 3-12h, P 18-24h, D 36-48h
TROP - O 3-13h, P 18-24h, D 10d |
|
|
Term
|
Definition
| MONA BAAA - morphine, O2 if low, nitro SL x3, ASA 325mg chewed, BB/metoprolol 25mg PO, atorvastatin 80mg PO, anti-PLT/tricagrelor, anti-coag |
|
|
Term
| how do you choose an anticoagulant in an MI |
|
Definition
| if going to PCI to heparin, if doing fibrinolytic do lovenox |
|
|
Term
| how do you management a suspected CVA - acronym |
|
Definition
| ACT GET CT - airway, circulation, temp, glucose, EKG, tox screen, CT |
|
|
Term
| when do you intubate in CVA - 2 |
|
Definition
| hypoventilation, vomiting |
|
|
Term
|
Definition
| <185/100, <200/100 if not getting thrombolytic, decrease 15% in 24h |
|
|
Term
| when does fever occurring during a CVA |
|
Definition
|
|
Term
| why is fever concerning during a CVA |
|
Definition
|
|
Term
| why do you get glucose in a suspected CVA |
|
Definition
| hypoglycemia can present like CVA |
|
|
Term
| when should CT be done in CVA |
|
Definition
|
|
Term
| other labs not in the acrynm you should get in a CVA - 6 |
|
Definition
| hCG, CBC, CMP, INR, PTT, cardiac enzymes, don't forget to oxygenate |
|
|
Term
| inclusion criteria for thrombolytic for CVA |
|
Definition
|
|
Term
| exclusion criteria for thrombolytic for CVA - 9 |
|
Definition
| trauma/CVA within last 3mo, concern for SAH, BP >180/110, active bleeding, warfarin with increased INR, heparin with increased PTT, low PLT, abnormal glucose, bleeding suggested on CT |
|
|
Term
|
Definition
| freidwald equation = LDL = total -HDL -(TG/5) |
|
|
Term
| what should you always correct before treating LDL |
|
Definition
|
|
Term
|
Definition
| total <170, LDL <100, HDL >45 |
|
|
Term
|
Definition
| total <200, LDL <100, HDL >50 |
|
|
Term
| management of hyperlipidemia 0-19yo |
|
Definition
| lifestyle modifications, assess for familial hyperlipidemia syndrome and treat if has that |
|
|
Term
| management of hyperlipidemia 29-30yo |
|
Definition
| lifestyle modifications, assess if early FHX hyperlpipidemia or assess if DL >160 |
|
|
Term
| management of HLD 40-75yo is guided by |
|
Definition
|
|
Term
| management of HLD based on ASCVD risk |
|
Definition
- <5% - lifestyle
- 5-7.5% - LS, Rx if risks
- 7.5-20% - LS, moderate statin (high dose if risks)
- >20% - LS, high dose statin |
|
|
Term
| what are 3 things where you would just jump to a high dose statin regardless of ASCVD |
|
Definition
| DM with risk factors, vascular disease, LDL >190 |
|
|
Term
| at what age do you consider not starting hyperlipidemia medications |
|
Definition
|
|
Term
| contraindications to statins - 3 |
|
Definition
| pregnancy, myopathy, liver disease |
|
|
Term
|
Definition
| elevated LFT, liver failure, muscle pain, rhabdo |
|
|
Term
|
Definition
|
|
Term
|
Definition
| atorvastatin 40/80mg, rotuvostatin 20/40mg |
|
|
Term
| moderate dose statins - 4 |
|
Definition
| atorvastatin 10/20mg, rotuvostatin 5/10, simvastatin 20/40, pravastatin 40/80 |
|
|
Term
| 3 things other than statins used to treat HLD |
|
Definition
| PC5K inhibitors (repatha, proluvent), O3 FA (vascepa, lovaza), emtricitibine |
|
|
Term
|
Definition
|
|
Term
| how much LDL is needed to really protect cardiovascular |
|
Definition
|
|
Term
| 2 things that increase LDL and which is best |
|
Definition
| niacin (increases it but no CV benefit), exercises (increases it and CV benefit) |
|
|
Term
| after starting statin when do you follow up and what is the goal |
|
Definition
| 6-12wk, LDL decreased by 50% (high dose) or 25% (mod dose), LDL <100 (or <70 if risk factors) |
|
|
Term
| what do you do if someone does not meet their LDL goals at follow up after statin |
|
Definition
| educate on lifestyle and medication adherence, follow up again 6wk, if still not meeting goal increase dose or add an agent |
|
|
Term
| if someone has HLD what labs should you get - 4 |
|
Definition
| glucose, TSH, hCG, urine protein |
|
|
